Innoviva ROA 2012-2025 | INVA
Current and historical return on assets (ROA) values for Innoviva (INVA) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Innoviva ROA - Return on Assets Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Total Assets | Return on Assets |
| 2025-09-30 | $0.13B | $1.43B | 9.55% |
| 2025-06-30 | $0.04B | $1.33B | 2.97% |
| 2025-03-31 | $-0.06B | $1.25B | -4.87% |
| 2024-12-31 | $0.02B | $1.30B | 1.83% |
| 2024-09-30 | $0.07B | $1.23B | 5.23% |
| 2024-06-30 | $0.15B | $1.23B | 11.86% |
| 2024-03-31 | $0.18B | $1.27B | 15.11% |
| 2023-12-31 | $0.18B | $1.24B | 15.38% |
| 2023-09-30 | $0.05B | $1.19B | 4.29% |
| 2023-06-30 | $0.23B | $1.12B | 19.47% |
| 2023-03-31 | $0.23B | $1.13B | 19.39% |
| 2022-12-31 | $0.22B | $1.23B | 17.90% |
| 2022-09-30 | $0.29B | $1.33B | 26.05% |
| 2022-06-30 | $0.10B | $1.14B | 9.76% |
| 2022-03-31 | $0.19B | $1.11B | 20.17% |
| 2021-12-31 | $0.27B | $0.93B | 28.73% |
| 2021-09-30 | $0.31B | $0.89B | 32.84% |
| 2021-06-30 | $0.27B | $0.79B | 27.90% |
| 2021-03-31 | $0.25B | $1.09B | 26.02% |
| 2020-12-31 | $0.22B | $1.00B | 24.96% |
| 2020-09-30 | $0.22B | $0.92B | 26.06% |
| 2020-06-30 | $0.23B | $0.88B | 29.72% |
| 2020-03-31 | $0.19B | $0.79B | 26.70% |
| 2019-12-31 | $0.16B | $0.73B | 24.00% |
| 2019-09-30 | $0.38B | $0.68B | 61.24% |
| 2019-06-30 | $0.38B | $0.64B | 74.44% |
| 2019-03-31 | $0.40B | $0.59B | 91.17% |
| 2018-12-31 | $0.40B | $0.55B | 109.85% |
| 2018-09-30 | $0.19B | $0.28B | 60.27% |
| 2018-06-30 | $0.17B | $0.34B | 48.62% |
| 2018-03-31 | $0.15B | $0.28B | 41.79% |
| 2017-12-31 | $0.13B | $0.37B | 35.22% |
| 2017-09-30 | $0.10B | $0.39B | 26.34% |
| 2017-06-30 | $0.09B | $0.37B | 24.31% |
| 2017-03-31 | $0.07B | $0.39B | 18.95% |
| 2016-12-31 | $0.06B | $0.38B | 15.57% |
| 2016-09-30 | $0.04B | $0.37B | 9.83% |
| 2016-06-30 | $0.02B | $0.38B | 4.46% |
| 2016-03-31 | $-0.01B | $0.39B | -1.18% |
| 2015-12-31 | $-0.02B | $0.41B | -4.45% |
| 2015-09-30 | $-0.04B | $0.44B | -8.37% |
| 2015-06-30 | $-0.06B | $0.46B | -11.05% |
| 2015-03-31 | $-0.11B | $0.49B | -20.64% |
| 2014-12-31 | $-0.17B | $0.52B | -29.56% |
| 2014-09-30 | $-0.20B | $0.55B | -33.20% |
| 2014-06-30 | $-0.23B | $0.61B | -35.81% |
| 2014-03-31 | $-0.20B | $0.61B | -31.57% |
| 2013-12-31 | $-0.17B | $0.68B | -26.84% |
| 2013-09-30 | $-0.15B | $0.67B | -27.18% |
| 2013-06-30 | $-0.14B | $0.60B | -28.66% |
| 2013-03-31 | $-0.14B | $0.59B | -32.11% |
| 2012-12-31 | $-0.02B | $0.37B | -5.26% |
| 2012-09-30 | $-0.02B | $0.38B | -7.62% |
| 2012-06-30 | $-0.02B | $0.40B | -6.90% |
| 2012-03-31 | $-0.01B | $0.22B | -3.01% |
| 2011-12-31 | $-0.12B | $0.26B | -40.00% |
| 2011-09-30 | $-0.10B | $0.28B | -31.82% |
| 2011-06-30 | $-0.09B | $0.30B | -30.29% |
| 2011-03-31 | $-0.08B | $0.32B | -30.80% |
| 2010-12-31 | $-0.08B | $0.33B | -32.75% |
| 2010-09-30 | $-0.09B | $0.21B | -39.73% |
| 2010-06-30 | $-0.09B | $0.23B | -41.61% |
| 2010-03-31 | $-0.09B | $0.25B | -43.41% |
| 2009-12-31 | $-0.09B | $0.18B | -43.31% |
| 2009-09-30 | $-0.08B | $0.18B | -37.62% |
| 2009-06-30 | $-0.08B | $0.21B | -34.21% |
| 2009-03-31 | $-0.08B | $0.22B | -33.64% |
| 2008-12-31 | $-0.09B | $0.24B | -35.07% |
| 2008-09-30 | $-0.11B | $0.26B | -44.49% |
| 2008-06-30 | $-0.12B | $0.28B | -51.80% |
| 2008-03-31 | $-0.14B | $0.30B | -64.44% |
| 2007-12-31 | $-0.16B | $0.16B | -77.85% |
| 2007-09-30 | $-0.16B | $0.20B | -71.54% |
| 2007-06-30 | $-0.17B | $0.21B | -67.33% |
| 2007-03-31 | $-0.17B | $0.25B | -59.23% |
| 2006-12-31 | $-0.17B | $0.26B | -55.33% |
| 2006-09-30 | $-0.17B | $0.29B | -58.47% |
| 2006-06-30 | $-0.17B | $0.32B | -63.67% |
| 2006-03-31 | $-0.16B | $0.33B | -65.51% |
| 2005-12-31 | $-0.14B | $0.23B | -62.51% |
| 2005-09-30 | $-0.13B | $0.20B | -53.28% |
| 2005-06-30 | $-0.11B | $0.23B | -46.34% |
| 2005-03-31 | $-0.11B | $0.26B | -59.73% |
| 2004-12-31 | $-0.10B | $0.29B | -83.10% |
| 2004-09-30 | $-0.09B | $0.21B | -175.61% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $1.454B | $0.359B |
| Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $981.687B | 47.22 |
| Johnson & Johnson (JNJ) | United States | $526.817B | 21.07 |
| AbbVie (ABBV) | United States | $378.839B | 22.68 |
| Roche Holding AG (RHHBY) | Switzerland | $345.602B | 0.00 |
| Novartis AG (NVS) | Switzerland | $304.907B | 16.16 |
| Novo Nordisk (NVO) | Denmark | $278.303B | 16.32 |
| Merck (MRK) | United States | $270.119B | 12.58 |
| Pfizer (PFE) | United States | $145.838B | 8.02 |
| Sanofi (SNY) | France | $113.633B | 10.99 |
| Bayer (BAYRY) | Germany | $50.890B | 8.93 |